贝利尤单抗与利妥昔单抗对系统性红斑狼疮患者健康相关生活质量的影响
研究纳入瑞典卡罗林斯卡大学医院接受贝利尤单抗(n=34)或利妥昔单抗(n=35)治疗的系统性红斑狼疮患者,前瞻性收集基线与第3、6、12、24个月的健康相关生活质量数据。两组患者基线时各维度均低于瑞典人群常模;贝利尤单抗组躯体成分总结从第12个月起显著改善(P=0.023),利妥昔单抗组心理成分总结第3个月即显著改善(P=0.031)。作者认为两组生活质量变化模式不同,可为生物制剂治疗的临床评估提供补充信息,并建议在更大队列中进一步研究抗疟药对生活质量的影响。
要点
- 两组患者基线时SF-36各维度均低于瑞典常模。
- 贝利尤单抗组躯体成分总结从第12个月起显著改善(P=0.023)。
- 利妥昔单抗组心理成分总结与疲劳第3个月即显著改善。
核心结论
- 研究结果证实系统性红斑狼疮患者存在相当程度的健康相关生活质量损害。
- 两组患者对健康相关生活质量的主观感受随时间呈现不同模式,可为生物制剂治疗的临床评估提供补充信息。
- 作者认为需要在更大队列中进一步研究抗疟药对系统性红斑狼疮患者健康相关生活质量的影响。
研究设计与样本
- 研究纳入瑞典卡罗林斯卡大学医院接受贝利尤单抗(n=34)或利妥昔单抗(n=35)治疗的系统性红斑狼疮患者。
- 对照采用按年龄和性别匹配的瑞典人群常模值。
- 数据在治疗开始时及第3、6、12、24个月前瞻性收集,使用SF-36、FACIT-疲劳量表、EQ-5D和Stanford健康评估问卷残疾指数(HAQ DI)。
主要发现
- 基线时SF-36所有维度均较瑞典常模明显降低。
- 贝利尤单抗组SF-36躯体成分总结从第12个月起显著改善(P=0.023),FACIT-疲劳到第24个月显著改善(P=0.001),EQ-5D评分无变化,HAQ DI到第6个月改善(P=0.014)。
- 利妥昔单抗组SF-36心理成分总结和FACIT-疲劳到第3个月即快速改善(分别为P=0.031和P=0.007),EQ-5D第6个月改善(P=0.016),HAQ DI第3个月改善(P=0.033)。
- 基线评估时,接受抗疟药的患者(n=33)在SF-36社会功能(P=0.022)和精神健康(P=0.023)维度优于未接受抗疟药的患者(n=36)。
局限性
- 作者认为需要在更大队列中进一步研究抗疟药对系统性红斑狼疮患者健康相关生活质量的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Accumulating evidence supports an impaired health-related quality of life (HRQoL) in patients with systemic lupus erythematosus (SLE). We investigated the effects of 2 biologic treatments on HRQoL of patients with SLE. METHODS: Patients with SLE from the Karolinska University Hospital treated with belimumab (n = 34) or rituximab (n = 35) were included; normative values derived from Swedish population-based controls matched for age and sex were used for the purpose of comparisons. Data were collected prospectively at treatment initiation and at months 3, 6, 12, and 24, using the Short Form 36 (SF-36) health questionnaire, the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale, the EuroQol 5-dimension (EQ-5D) instrument, and the Stanford Health Assessment Questionnaire disability index (HAQ DI). RESULTS: Substantial decrements from Swedish norms were observed across all SF-36 domains at baseline. Patients treated with belimumab reported gradual improvements in the SF-36 physical component summary (significant from month 12; P = 0.023) and FACIT-Fatigue (significant by month 24; P = 0.001), no changes in EQ-5D scores, and improvements in HAQ DI by month 6 (P = 0.014). Patients treated with rituximab showed rapid improvements in the SF-36 mental component summary and FACIT-Fatigue by month 3 (P = 0.031 and P = 0.007, respectively), as well as improvements in EQ-5D at month 6 (P = 0.016) and HAQ DI at month 3 (P = 0.033). Based on baseline evaluations, patients receiving antimalarial agents (n = 33) performed better in the SF-36 social functioning (P = 0.022) and mental health (P = 0.023) domains compared to patients who did not receive antimalarial agents (n = 36). CONCLUSION: Our results corroborated previous findings of considerable HRQoL impairments in patients with SLE. Patients' perceptions of HRQoL showed discrepant patterns over time in the 2 treatment groups and could provide additional information along with the clinical evaluation of biologic therapy in SLE. Further survey on the effects of antimalarial agents on the HRQoL of patients with SLE in larger cohorts is merited.
引用
- Parodis I, Lopez Benavides AH, Zickert A, et al. The Impact of Belimumab and Rituximab on Health-Related Quality of Life in Patients With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2019. PMID: 30055091. doi:10.1002/acr.23718
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。